Therefore, further analysis of the differences in the expression of various ERs in key brain regions associated with depression and the affinity preferences of estrogen alternative therapeutic drugs for these ERs will help determine the most appropriate ER target for developing antidepressant therapies. Here, ESR1 is linked to depressive symptom measurement.